AEZS

Aeterna Zentaris Inc
5.12
0.00 (0.00%)

AEterna Zentaris Inc. (AEZS) Fundamentals

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.
SHARE INFORMATION
Market Cap$ 24,862,085
Shares Outstanding4,855,876
Float4,851,119
Percent Float99.9%
Short Interest2,438.00
Short Percent Float100.0%
Short Interest Ratio1.3884
Short Interest Date2023-01-31
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 6,648,192
Latest Fiscal EPS$ -2.21
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions33
Institutional Holdings Date2023-01-31
Institutional Bought Previous 3 Months1,996
Institutional Holdings Percent0.7%
Institutional Sold Previous 3 Months3
Insider Holdings Date-
Insider Bought Previous 3 Months-
Insider Holdings Percent0.0
Insider Sold Previous 3 Months-
Insider Shares Owned2,519,925
TRADING INFO
52 Week High$ 13.50
52 Week Low$ 4.00
52 Week High Change$ -55.48
21 Day Moving Average$ 5.0433
21 Day Extended Moving Average$ 5.0041
50 Day Moving Average$ 4.8848
50 Day Extended Moving Average$ 4.9849
200 Day Moving Average$ 5.9519
200 Day Extended Moving Average$ 6.859
10 Day Average Volume1,455
20 Day Average Volume936
30 Day Average Volume1,350
50 Day Average Volume2,164
Alpha-0.02187
Beta1.721966
Standard Deviation0.24941
R20.098719
7 Day Price Change$ -0.03
7 Day Percent Change-0.58%
21 Day Price Change$ -0.12
21 Day Percent Change-2.29%
30 Day Price Change$ 0.31
30 Day Percent Change6.44%
Month to Date Price Change$ -0.06
Month to Date Percent Change-1.16%
Quarter to Date Price Change$ 0.82
Quarter to Date Percent Change19.07%
180 Day Price Change$ -1.26
180 Day Percent Change-19.75%
200 Day Price Change$ -0.52
200 Day Percent Change-9.22%
Year to Date Price Change$ 0.82
Year to Date Percent Change19.07%

AEterna Zentaris Inc. (AEZS) Key Ratios

PROFITABILITY
EBIT Margin-344.6%
EBITDA Margin-341.1%
Pre-Tax Profit Margin-289.4%
Profit Margin Count0.0%
Gross Margin97.0%
Profit Margin TOT0.0%
INCOME STATEMENTS
Revenue$ 4,364,216
Revenue Per Share$ 0.89875
Revenue (3 Years)$ 88.32
Revenue (5 Years)$ 15.11
FINANCIAL STRENGTH
Price to Tangible Book0.43
Total Debt To Equity0.00
Int Coverage191,002.20
Current Ratio9.80
Leverage Ratio1.40
Quick Ratio9.40
Long Term Debt To Capital0.00
VALUATION MEASURES
PE Ratio-1.50
Enterprise Value$ -46,546,179
Price to Sales5.6968
Price to Free Cash-1.80
PE High Last 5 Years21.90
Price To Book0.38
Price To Cash Flow9.90
PE Low Last 5 Years-2.90
Price to Tangible Book0.43
MANAGEMENT EFFECTIVENESS
Receivables Turnover0.70
Invoice Turnover0.80
Assets Turnover0.00
Return Assets-17.72
Return on Equity-24.09
Return on Capital-24.03

AEterna Zentaris Inc. (AEZS) Profile

PROFILE INFO
Issue TypeCS
SEC TypeEQS
AuditorErnst & Young LLP
CEOKlaus Paulini
Emplyoees17
Last AuditUQ
CIK0001113423
IndustryBiotechnology
SectorHealthcare
NAICSPharmaceutical Preparation Manufacturing(325412)
CONTACT INFO
Addressc/o Norton Rose Fulbright Canada, LLP
222 Bay Street
Toronto, ON M5K 1E7
Websitehttps://www.zentaris.com
Facsimile-
Telephone+1 843 900-3223
EmailIR@aezsinc.com


Your Recent History
TSX
AEZS
Aeterna Ze..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.